Kymera Therapeutics, Inc. KYMR
Updated: 10 Sep 2026
No signal published yet
We already track Kymera Therapeutics and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.
Email when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Temporary check — not Firelda's published signal.
General analysis — not personal advice.
Want to follow Kymera Therapeutics, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Kymera Therapeutics free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Recent News
On August 5, 2026, Kymera reported its second quarter 2026 financial results with collaboration revenue reaching $65 million and a cash position of $1.5 billion. The company also announced that patient enrollment for its KT-621 Phase 2b BROADEN2 trial was completed ahead of schedule. Topline data from the study is now expected by year-end 2026.
What Firelda Watch includes for Kymera Therapeutics, Inc.
Add the company to your watchlist and get all of this automatically.
- Free: 3 companies on your watchlist
- Change history and monitoring for every company you follow
- Sunday weekly brief — a short weekly roundup
- Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
Want to follow Kymera Therapeutics, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Kymera Therapeutics free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more